Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam
Model scores of the 29,894 trials active now.
Model score 3% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).
Finished trial that started in 2015 or later: the model never saw it during training.
How it ended
Completed on 2019-02-19, after 2017-11-29 start.
The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-02-19. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Accepts healthy volunteers: Yes (lowers risk) · Who can join
-
Wording of the registration (title, summary, criteria) (lowers risk) · Wording
Phrases that raised it: livertumorsor equalequal toheart
Phrases that lowered it: healthyadministrationdrugdiseasesfixed -
Primary purpose: other (lowers risk) · Design
-
Phase: 1 (lowers risk) · Design
-
Drug's FAERS reports marked serious: 41.1% (lowers risk) · Drug's FDA history
-
Design: parallel (raises risk) · Design
-
Trials the sponsor started in the prior 2 years: 124 (lowers risk) · Sponsor's track record
-
Sponsor's past termination rate: 7.0% (lowers risk) · Sponsor's track record
-
Sponsor's past trials: 761 (raises risk) · Sponsor's track record
-
Minimum age: 45 (lowers risk) · Who can join
-
Drug's FAERS reports with a death: 2.4% (lowers risk) · Drug's FDA history
-
Has a data monitoring committee: No (lowers risk) · Design
-
Sponsor type: industry (lowers risk) · Sponsor's track record
-
Blinding: none (lowers risk) · Design
-
Number of arms: 5 (lowers risk) · Design
-
Disease area, cancer: No (lowers risk) · Disease area
-
Maximum age: 70 (raises risk) · Who can join
-
Drug's FAERS reports in the prior 12 months: 20456 (raises risk) · Drug's FDA history
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 1 (typical: 2)
- Number of arms
- 5 (typical: 2)
- Allocation
- randomized
- Design
- parallel
- Primary purpose
- other (typical: treatment)
- Blinding
- none
- Has a data monitoring committee
- No (typical: 56% yes)
- Responsible party
- sponsor
- Collaborators
- 0
- Keywords listed
- 0 (typical: 1)
Who can join
- Minimum age
- 45 (typical: 18)
- Maximum age
- 70 (typical: 71)
- Sex
- female (typical: all)
- Accepts healthy volunteers
- Yes (typical: 9% yes)
Sponsor's track record
- Sponsor type
- industry (typical: academic or other)
- Sponsor's past trials
- 761 (typical: 32)
- Sponsor's past termination rate
- 7.0% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 124 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 9 (typical: 1)
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 169657 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 20456 (typical: 412.5)
- Drug's FAERS reports marked serious
- 41.1% (typical: 85.6%)
- Drug's FAERS reports with a death
- 2.4% (typical: 15.9%)
Disease area and drugs
- Disease areas
- none of the 14 tracked areas
- Drugs matched to FDA substances
- desogestrel, dienogest, drospirenone, ethinyl estradiol, levonorgestrel, midazolam, midazolam midazolam, norethindrone
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate NCT00955760 · started 2009 · scored riskier than 3% of active trials completed
- A Comparative Study of Rupatadine 10 mg Tablets and Clarinex® 5 mg Tablets Under Fasting Conditions NCT05356143 · started 2021 · scored riskier than 2% of active trials completed
- A Drug Interaction Study of SY-004 Capsules in Healthy Subjects NCT04907019 · started 2021 · scored riskier than 1% of active trials completed
- A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib NCT03398421 · started 2018 · scored riskier than 1% of active trials completed
- A Drug-drug Interaction Trial of Rifampicin Pharmacokinetics Effect on Fluzoparib NCT04011124 · started 2019 · scored riskier than 2% of active trials completed
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.